Advances in Radiotherapy for Extensive-stage Small Cell Lung Cancer
in the Era of Immunotherapy.
10.3779/j.issn.1009-3419.2025.102.20
- Author:
Tingting CHEN
1
;
Yanling YANG
1
;
Haonan HAN
2
;
Dongmin LIU
1
;
Yajing YUAN
3
;
Liming XU
1
Author Information
1. Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
2. Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Sciences, China Three Gorges University, Yichang 443002, China.
3. Department of Anesthesiology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
- Publication Type:English Abstract
- Keywords:
Extensive-stage small cell lung cancer;
Immunotherapy;
Lung neoplasms;
Radiotherapy
- MeSH:
Humans;
Small Cell Lung Carcinoma/therapy*;
Lung Neoplasms/therapy*;
Immunotherapy;
Neoplasm Staging;
Radiotherapy/methods*;
Combined Modality Therapy
- From:
Chinese Journal of Lung Cancer
2025;28(5):353-362
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer (SCLC) is the thoracic malignant tumor and accounts for about 15% of lung malignancies and transfer often occurs by the time of diagnosis. Extensive stage-small cell lung cancer (ES-SCLC) accounts for about 2/3 of all SCLC. For many years, radiotherapy has occupied an important position in the treatment of SCLC, especially in the treatment of ES-SCLC, because SCLC is more sensitive to radiotherapy. However, in recent years, immune checkpoint inhibitor has shown more excellent antitumor activity in the treatment of ES-SCLC and become the mainstream argument for the treatment of ES-SCLC. However, will radiotherapy be buried by the times among the therapeutic approaches for ES-SCLC? In this article, we will review the clinical progress of radiotherapy, immunotherapy and combination therapy for ES-SCLC.
.
